Testimonials

It is very nice to visit Lambda facility and thanks to warm welcome provided by all the teams. I can easily say one of the best CRO I ever visited. People here are wonderful and doing great job

Reputed Client of Israel

Awesome hospitality & fantastic office. All the best!

Reputed Client of Japan

Excellent hospitality and cooperation received throughout the audit. People are knowledgeable and extremely transparent. Looking for long time relation

Reputed Client of Asia

Facility is too good to conduct the BABE studies and adherence to protocol and quality assurance in conducting studies are meeting sponsor expectations and requirements.

Reputed Client of India

Facility is good, people r trained well and know the subject on which they r working. All the best.

Reputed Client of USA

Highly innovative and advanced research centre that possess bright future for the development of the country.

Reputed International Government Body

It is one of the best facility in India for BA/BE

Reputed Regulatory Authority

Lambda is a very professional CRO. All the staff here are experienced and very knowledgeable. I'm grateful for their accommodations and hospitality. The future, if we want to carry out BE study, we will ask Lambda help again.

Reputed Client of Europe

It was a really pleasant meeting with the PV department, and I am looking forward to the next visit.

Reputed Client of Europe

Amazing and best CRO I ever seen

Reputed Client of China

Company News

Company News

Home / Company News

Lambda Therapeutic Research successfully clears another European Medicines Agency (EMA) Inspection for two PK studies in Oncology on Metastatic Breast Cancer and Ovarian Cancer patients

11 Dec 2021

It is with great pride we announce that we have successfully cleared an important EMA inspection for a PK study in Oncology segment on Metastatic Breast Cancer and Ovarian Cancer patients by DKMA [Danish Medicines Agency, Denmark] and INFARMED [National Authority of Medicines and Health Products, Portugal]. We also had the unique privilege of having the USFDA inspectors participate in the same Inspection since they were invited by the EMA Authorities as observers.

Overall, the inspection was conducted in two phases of which the 1st Phase (28 to 30 June 2021) was a virtual inspection; wherein our IT systems were meticulously reviewed and the 2nd Phase (18 to 29 Oct 2021) comprised of a physical onsite inspection of our clinical Sites and bioanalytical facilities.

Besides being another glittering testament to the consistently high quality standards of Clinical Research services provided to our Global clientele, this milestone also reinforces Lambda's commitment to uncompromising compliance with global regulations and guidelines for Good Clinical Practice (GCP).

We look forward to your continued patronage to achieve more milestones of quality excellence in the global Clinical Research landscape.